Adjuvant Chemotherapy

Women aged 65 years or younger who underwent surgery and adjuvant chemotherapy for gynecologic cancer appeared at higher risk for osteopenia and osteoporosis as early as 1 year after treatment, according to study results presented at the virtual Society of Gynecologic Cancer Annual Meeting.

Neoadjuvant chemotherapy did not appear to expedite treatment compared with adjuvant chemotherapy for women with breast cancer, according to study findings published in Cancer Medicine.

A single course of adjuvant bleomycin, etoposide and cisplatin chemotherapy appeared safe and effective among a cohort of men with high-risk primary testicular cancer, according to results of the phase 3, single-arm, prospective 111 study published in European Urology.

The Affordable Care Act’s dependent coverage expansion provision has resulted in earlier-stage diagnosis and more timely receipt of adjuvant chemotherapy among young patients with colorectal cancer, according to results of a retrospective study published in Journal of the National Cancer Institute.

Early adjuvant chemotherapy dose reductions appeared to adversely affect survival outcomes among women with intermediate- or high-risk breast cancer, according to results of a retrospective study published in Journal of the National Comprehensive Cancer Network.

Erdafitinib induced a high rate of objective tumor response in patients with locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alterations, according to results of a single-arm phase 2 study published in The New England Journal of Medicine.

  Healio spoke to Kevin M. Elias, MD, director of the Gynecologic Oncology Laboratory at Brigham and Women's Hospital and assistant professor of obstetrics, gynecology and reproductive biology at Harvard Medical School, about screening for endometrial cancer.